  Tumor burden is a key consideration for the treatment of solid malignancies. Large baseline tumor size ( an assessment of volume of disease in target lesions<symptom> prior to treatment) , elevated LDH , and site of disease are prognostic of poor overall survival for patients with advanced melanoma treated with pembrolizumab.